Therefore, inhibitors of pro-survival BCL2 family proteins should have a therapeutic index based on synergy with the effects of sirolimus in targeted therapy for “primed” NF1/PTEN-mutant tumor cells, while sparing normal tissues. This evidence concerns the gene NF1 and neoplasm.